K. Ulrich Bayer

Tenured Full Professor

University of Colorado Anschutz Medical Campus

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

K. Ulrich Bayer is a Tenured Full Professor at the University of Colorado - Anschutz Medical Campus, USA. His research focuses on calcium/calmodulin-dependent protein kinase II (CaMKII) and its role in synaptic plasticity, memory, and learning. Recent articles authored by Professor Bayer explore various aspects of CaMKII mechanisms, synaptic potentiation, and neuroprotective effects in pathological conditions.

Articles (12)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (1)

Carolyn Nicole Brown

Professional Research Assistant/Lab Manager

University of Colorado Boulder

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

K. Ulrich Bayer

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

CaMKII mechanisms that promote pathological LTP impairments

The neuroprotective γ-hydroxybutyrate analog 3-hydroxycyclopent-1-enecarboxylic acid does not directly affect CaMKIIα autophosphorylation at T286 or binding to GluN2B

A revised view of the role of CaMKII in learning and memory

LTP expression mediated by autonomous activity of GluN2B-bound CaMKII

Stimulating β-adrenergic receptors promotes synaptic potentiation by switching CaMKII movement from LTD to LTP mode

Distinct synaptic pools of DAPK1 differentially regulate activity-dependent synaptic CaMKII accumulation

CaMKII T286 phosphorylation has distinct essential functions in three forms of long-term plasticity

Aβ-induced synaptic impairments require CaMKII activity that is stimulated by indirect signaling events

Characterization of six CaMKIIα variants found in patients with schizophrenia

GluN2B S1303 phosphorylation by CaMKII or DAPK1: No indication for involvement in ischemia or LTP

CaMKII holoenzyme mechanisms that govern the LTP versus LTD decision

The CaMKII K42M and K42R mutations are equivalent in suppressing kinase activity and targeting

Collaborators (1)

Carolyn Nicole Brown

Make your next move.